<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01664663</url>
  </required_header>
  <id_info>
    <org_study_id>PLANET</org_study_id>
    <nct_id>NCT01664663</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy</brief_title>
  <acronym>PLANET</acronym>
  <official_title>Phase II Randomized Study on Locally Advanced Non Small Cell Lung Cancer Escalated Dose on Individual Basis Treatment With Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ass. Prof. Jan Nyman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Lung Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the valu of individually dose escalated radiotherapy
      compared with a standard dose of radiotherapy combined with standard concomitant chemotherapy
      for patients with locally advanced non small cell lung cancer (stage III) with good
      performance status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicentre phase II trial of individually escalated radiotherapy up
      to 84 Gy due to normal tissue dose constraints combined with standard concurrent chemotherapy
      (cisplatin-vinorelbine) compared to standard dose radiotherapy (68 Gy) combined with the same
      chemotherapy. There are restrictions due to lung function, performance status and
      pre-treatment weight loss. The main endpoint is progression free survival and additional
      endpoints are local control, overall survival, toxicity quality of life and relapse pattern.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety analysis showed increased grade 5 toxicity in experimental arm.
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>36 monts after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients without progression of locoregional disease</measure>
    <time_frame>36 months after randomization</time_frame>
    <description>Measured with CT-scan according to the RECIST criteria for response</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Numbers of patients with adverse events</measure>
    <time_frame>Up to 36 months after randomization</time_frame>
    <description>According to CTC version 4.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 36 months after randomization</time_frame>
    <description>Measured by questionaires, EORTC QLQ 30 + LC 14</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Locally Advanced Disease</condition>
  <arm_group>
    <arm_group_label>Arm A:Standard radiochemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Escalated radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radiochemotherapy to 68 Gy</intervention_name>
    <arm_group_label>Arm A:Standard radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dose escalated radiochemotherapy up to 84 Gy</intervention_name>
    <arm_group_label>Arm B Escalated radiochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of NSCLC stage IIIA-B.

          -  Nonresectable or medically inoperable patients.

          -  No prior chemo- or radiotherapy for NSCLC.

          -  PS 0-1.

          -  FEV1 &gt; 1 l or &gt; 40% and CO diffusion capacity &gt; 40%.

          -  Patient compliance and geographic proximity that allow adequate follow-up.

          -  Adequate bone marrow reserve: WBCC &gt;3.0, platelets &gt;100, haemoglobin &gt; 100.

          -  Written informed concent.

          -  Effective use of contraception.

        Exclusion Criteria:

          -  Excessive weight loss within 6 months (&gt; 10%).

          -  Supraclavicular nodes.

          -  Apical tumors-pancoast.

          -  T4 tumors with separate manifestations in different lobes.

          -  Evidence of active serious infections.

          -  Inadequate liver function.

          -  Inadequate kidney function.

          -  Pregnancy.

          -  Breast feeding.

          -  Serious concomitant systemic disorder.

          -  Second primary malignancy the last 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Nyman, Ass. prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Lung Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <state>Norrland</state>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholm county</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2012</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2012</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Swedish Lung Cancer Study Group</investigator_affiliation>
    <investigator_full_name>Ass. Prof. Jan Nyman</investigator_full_name>
    <investigator_title>Assosiated professor Jan Nyman, Department of Oncology, Sahlgrenska University Hospital, Gotenburg , Sweden</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Normal tissue constraints</keyword>
  <keyword>Locally advanced disease</keyword>
  <keyword>Good performance status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

